Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances

doi:10.5306/wjco.v13.i6.448

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4629)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

306

WORD

HTML

2889

Figures (1-2)

227

Tables (1-4)

183

Sum=3676

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

327

Download

626

Sum=953

Jun 24, 2022 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Jun 24, 2022; 13(6): 448-472
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.448

Table 2 Ongoing clinical trials investigating combinations of immune checkpoint inhibitors and anti-vascular endothelial growth factors factors

NCT	Phase		Study drugs	Treatment line	Endpoint	Estimated End of Trial
NCT03794440		2/3	SINTILIMAB + BEVACIZUMABBIOSIMILAR	1	OS, ORR	December 2022
NCT03970616		1b/2	DURVALUMAB + TIVOZANIB	1	Safety	August 2022
NCT03973112		2	HLX-10+BEVACIZUMAB BIOSIMILAR	1	ORR	June 2022

NCT: Number of the clinical trial (Clinicaltrials.gov); OS: Overall survival; ORR: Overall response rate.

Citation: Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472
URL: https://www.wjgnet.com/2218-4333/full/v13/i6/448.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i6.448